Aspira Pathlab & Diagnostics Limited
Fundamental Score
Aspira Pathlab & Diagnostics Limited Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ASPIRA across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Return on Equity (32.96%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (17.04%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Attractive Valuation (P/E: 29.92 vs Industry: 39.28)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (740.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
4 factors identified
Elevated Debt Levels (D/E: 1.12)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability and cash flow generation.
Low Promoter Commitment (18.39%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment and long-term vision alignment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Aspira Pathlab & Diagnostics Limited
About ASPIRA
Business Overview
Aspira Pathlab & Diagnostics Limited owns, manages, runs, and administers various diagnostics centers primarily in India. The company offers biochemistry, hematology, histopathology, microbiology, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigation services. It also provides sonography, x-ray, and radiology tests. The company was formerly known as Utkal Soap Products Limited and changed its name to Aspira Pathlab & Diagnostics Limited in November 2016. Aspira Pathlab & Diagnostics Limited was incorporated in 1973 and is based in Mumbai, India.
Company Details
Key Leadership
Latest News
ASPIRA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Aspira Pathlab & Diagnostics Limited (ASPIRA)?
As of 30 Jan 2026, 01:40 pm IST, Aspira Pathlab & Diagnostics Limited (ASPIRA) is currently trading at ₹63.70. The stock has a market capitalization of ₹71.80 (Cr).
Is ASPIRA share price Overvalued or Undervalued?
ASPIRA is currently trading at a P/E ratio of 29.92x, compared to the industry average of 39.28x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Aspira Pathlab & Diagnostics Limited share price?
Key factors influencing ASPIRA's price include its quarterly earnings growth (Sales Growth: 13.15%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Aspira Pathlab & Diagnostics Limited a good stock for long-term investment?
Aspira Pathlab & Diagnostics Limited shows a 5-year Profit Growth of N/A% and an ROE of 32.96%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.12 before investing.
How does Aspira Pathlab & Diagnostics Limited compare with its industry peers?
Aspira Pathlab & Diagnostics Limited competes with major peers in the Healthcare Service Provider. Investors should compare ASPIRA's P/E of 29.92x and ROE of 32.96% against the industry averages to determine its competitive standing.
What is the P/E ratio of ASPIRA and what does it mean?
ASPIRA has a P/E ratio of 29.92x compared to the industry average of 39.28x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹30 for every ₹1 of annual earnings.
How is ASPIRA performing according to Bull Run's analysis?
ASPIRA has a Bull Run fundamental score of 24.7/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does ASPIRA belong to?
ASPIRA operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Aspira Pathlab & Diagnostics Limited.
What is Return on Equity (ROE) and why is it important for ASPIRA?
ASPIRA has an ROE of 32.96%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Aspira Pathlab & Diagnostics Limited generates profits from shareholders' equity.
How is ASPIRA's debt-to-equity ratio and what does it indicate?
ASPIRA has a debt-to-equity ratio of 1.12, which indicates high leverage that increases financial risk. A ratio below 1.0 generally indicates conservative financing.
What is ASPIRA's dividend yield and is it a good dividend stock?
ASPIRA offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has ASPIRA grown over the past 5 years?
ASPIRA has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in ASPIRA and why does it matter?
Promoters hold 18.39% of ASPIRA shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is ASPIRA's market capitalization category?
ASPIRA has a market capitalization of ₹72 crores, placing it in the Small-cap category.
How volatile is ASPIRA stock?
ASPIRA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for ASPIRA?
ASPIRA has a 52-week high of ₹N/A and low of ₹N/A.
What is ASPIRA's operating profit margin trend?
ASPIRA has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is ASPIRA's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 13.15% and YoY Profit Growth of 740.00%.
What is the institutional holding pattern in ASPIRA?
ASPIRA has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.